NCT00197236 - Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months | Biotech Hunter

Enrollment

468

Participants

Timeline

Start Date

November 11, 2003

Primary Completion Date

December 3, 2007

Study Completion Date

December 3, 2007

Conditions

Hepatitis A

Interventions

BIOLOGICAL

Havrix™

2 intramuscular injections, 6 months apart

BIOLOGICAL

Infanrix™

1 intramuscular injection

BIOLOGICAL

ActHIB™

1 intramuscular injection

Trial Locations (22)

14850

GSK Investigational Site, Ithaca

15202

GSK Investigational Site, Bellevue

15213

GSK Investigational Site, Pittsburgh

15241

GSK Investigational Site, Pittsburgh

17033

GSK Investigational Site, Hershey

19810

GSK Investigational Site, Wilmington

23111

GSK Investigational Site, Mechanicsville

24549

GSK Investigational Site, Danville

29425

GSK Investigational Site, Charleston

30907

GSK Investigational Site, Martinez

33027

GSK Investigational Site, Pembroke Pines

44501

GSK Investigational Site, Youngstown

50702

GSK Investigational Site, Waterloo

54601

GSK Investigational Site, La Crosse

58501

GSK Investigational Site, Bismarck

71111

GSK Investigational Site, Bossier City

75235

GSK Investigational Site, Dallas

77701

GSK Investigational Site, Beaumont

85029

GSK Investigational Site, Phoenix

94583

GSK Investigational Site, San Ramon

94612

GSK Investigational Site, Oakland

07740

GSK Investigational Site, Long Branch